BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hadryś A, Sochanik A, McFadden G, Jazowiecka-Rakus J. Mesenchymal stem cells as carriers for systemic delivery of oncolytic viruses. Eur J Pharmacol 2020;874:172991. [PMID: 32044323 DOI: 10.1016/j.ejphar.2020.172991] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Reale A, Calistri A, Altomonte J. Giving Oncolytic Viruses a Free Ride: Carrier Cells for Oncolytic Virotherapy. Pharmaceutics 2021;13:2192. [PMID: 34959474 DOI: 10.3390/pharmaceutics13122192] [Reference Citation Analysis]
2 Nethi SK, Bhatnagar S, Prabha S. Synthetic Receptor-Based Targeting Strategies to Improve Tumor Drug Delivery. AAPS PharmSciTech 2021;22:93. [PMID: 33683499 DOI: 10.1208/s12249-021-01919-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Kenarkoohi A, Bamdad T, Soleimani M, Soleimanjahi H, Fallah A, Falahi S. HSV-TK Expressing Mesenchymal Stem Cells Exert Inhibitory Effect on Cervical Cancer Model. Int J Mol Cell Med 2020;9:146-54. [PMID: 32934952 DOI: 10.22088/IJMCM.BUMS.9.2.146] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
4 Jin KT, Du WL, Liu YY, Lan HR, Si JX, Mou XZ. Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements. Cancers (Basel) 2021;13:588. [PMID: 33546172 DOI: 10.3390/cancers13040588] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Chung H, Jung H, Noh JY. Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy. Int J Mol Sci 2021;22:12126. [PMID: 34830003 DOI: 10.3390/ijms222212126] [Reference Citation Analysis]
6 Aldrak N, Alsaab S, Algethami A, Bhere D, Wakimoto H, Shah K, Alomary MN, Zaidan N. Oncolytic Herpes Simplex Virus-Based Therapies for Cancer. Cells 2021;10:1541. [PMID: 34207386 DOI: 10.3390/cells10061541] [Reference Citation Analysis]
7 Blanco-Fernandez B, Cano-Torres I, Garrido C, Rubi-Sans G, Sanchez-Cid L, Guerra-Rebollo M, Rubio N, Blanco J, Perez-Amodio S, Mateos-Timoneda MA, Engel E. Engineered microtissues for the bystander therapy against cancer. Mater Sci Eng C Mater Biol Appl 2021;121:111854. [PMID: 33579487 DOI: 10.1016/j.msec.2020.111854] [Reference Citation Analysis]
8 Fontana F, Bartolo R, Santos HA. Biohybrid Nanosystems for Cancer Treatment: Merging the Best of Two Worlds. Adv Exp Med Biol 2021;1295:135-62. [PMID: 33543459 DOI: 10.1007/978-3-030-58174-9_7] [Reference Citation Analysis]
9 Wang X, Zhao X, He Z. Mesenchymal stem cell carriers enhance anti-tumor efficacy of oncolytic virotherapy. Oncol Lett 2021;21:238. [PMID: 33664802 DOI: 10.3892/ol.2021.12499] [Reference Citation Analysis]
10 Zhang Y, Li Y, Chen K, Qian L, Wang P. Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy. Cancer Cell Int 2021;21:262. [PMID: 33985527 DOI: 10.1186/s12935-021-01972-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 McKenna MK, Englisch A, Brenner B, Smith T, Hoyos V, Suzuki M, Brenner MK. Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity. Mol Ther 2021;29:1808-20. [PMID: 33571680 DOI: 10.1016/j.ymthe.2021.02.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Morales-Molina A, Rodríguez-Milla MÁ, Gimenez-Sanchez A, Perisé-Barrios AJ, García-Castro J. Cellular Virotherapy Increases Tumor-Infiltrating Lymphocytes (TIL) and Decreases their PD-1+ Subsets in Mouse Immunocompetent Models. Cancers (Basel) 2020;12:E1920. [PMID: 32708639 DOI: 10.3390/cancers12071920] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
13 Morales-Molina A, Gambera S, Leo A, García-Castro J. Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma. J Immunother Cancer 2021;9:e001703. [PMID: 33737338 DOI: 10.1136/jitc-2020-001703] [Reference Citation Analysis]
14 Jazowiecka-Rakus J, Hadrys A, Rahman MM, McFadden G, Fidyk W, Chmielik E, Pazdzior M, Grajek M, Kozik V, Sochanik A. Myxoma Virus Expressing LIGHT (TNFSF14) Pre-Loaded into Adipose-Derived Mesenchymal Stem Cells Is Effective Treatment for Murine Pancreatic Adenocarcinoma. Cancers (Basel) 2021;13:1394. [PMID: 33808692 DOI: 10.3390/cancers13061394] [Reference Citation Analysis]
15 Liu H, Luo H. Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges. Viruses 2021;13:1082. [PMID: 34198859 DOI: 10.3390/v13061082] [Reference Citation Analysis]
16 Wang X, Yang Y, Wang N, Wu X, Xu J, Zhou Y, Zhao X, He Z. Mesenchymal stem cell carriers enhance antitumor efficacy induced by oncolytic reovirus in acute myeloid leukemia. Int Immunopharmacol 2021;94:107437. [PMID: 33571747 DOI: 10.1016/j.intimp.2021.107437] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Chew HY, Chan V, Simpson F, Dolcetti R. Will Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit? Cancers (Basel) 2020;12:E3392. [PMID: 33207697 DOI: 10.3390/cancers12113392] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
18 Hassanzadeh A, Altajer AH, Rahman HS, Saleh MM, Bokov DO, Abdelbasset WK, Marofi F, Zamani M, Yaghoubi Y, Yazdanifar M, Pathak Y, Chartrand MS, Jarahian M. Mesenchymal Stem/Stromal Cell-Based Delivery: A Rapidly Evolving Strategy for Cancer Therapy. Front Cell Dev Biol 2021;9:686453. [PMID: 34322483 DOI: 10.3389/fcell.2021.686453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Jazowiecka-Rakus J, Sochanik A, Rusin A, Hadryś A, Fidyk W, Villa N, Rahman MM, Chmielik E, Franco LS, McFadden G. Myxoma Virus-Loaded Mesenchymal Stem Cells in Experimental Oncolytic Therapy of Murine Pulmonary Melanoma. Mol Ther Oncolytics 2020;18:335-50. [PMID: 32775618 DOI: 10.1016/j.omto.2020.07.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Zhang J, Yuan Z, Zhong W, Wei Y. Stem Cell as Vehicles of Antibody in Treatment of Lymphoma: a Novel and Potential Targeted Therapy. Stem Cell Rev Rep 2021;17:829-41. [PMID: 33205352 DOI: 10.1007/s12015-020-10080-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]